George Borst, MD
Endocrinology, Diabetes & Metabolism · Ashland, KYNPI 1144273350
Payments from drug & device makers
Across 502 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Abbott$846
- AbbVie$522
- Sanofi-aventis U.S. LLC$501
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,088100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $1,364 |
| Lilly USA, LLC | 66 | $1,064 |
| AstraZeneca(2 entities) | 70 | $1,053 |
| Abbott | 49 | $846 |
| AbbVie | 32 | $522 |
| Sanofi-aventis U.S. LLC | 34 | $501 |
| Medtronic(2 entities) | 23 | $386 |
| Dexcom, Inc. | 13 | $315 |
| Amgen | 17 | $262 |
| Boehringer Ingelheim | 16 | $233 |
| Corcept Therapeutics | 10 | $191 |
| Esperion Therapeutics, Inc. | 12 | $175 |
| Merck | 11 | $142 |
| Xeris Pharmaceuticals, Inc. | 8 | $135 |
| Insulet Corporation | 6 | $126 |
| Amneal Pharmaceuticals LLC | 6 | $108 |
| IBSA Pharma Inc. | 7 | $108 |
| Tandem Diabetes Care, Inc. | 5 | $101 |
| Ascendis Pharma Endocrinology Inc | 4 | $66 |
| Amarin Pharma, Inc. | 5 | $65 |
| Ultragenyx Pharmaceutical Inc. | 3 | $49 |
| Novartis | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Bayer | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Valeritas, Inc. | 1 | $19 |
| BD | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| BETA Bionics, Inc. | 1 | $14 |
| Sequel Med Tech, LLC | 1 | $14 |
| Medicure Pharma Inc. | 1 | $12 |
How this compares
$8,100 in reported general payments places this provider in the 65th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $178,222 |
| MounjaroTirzepatide | 125 | $153,403 |
| JardianceEmpagliflozin | 62 | $81,058 |
| TrulicityDulaglutide | 43 | $80,380 |
| FarxigaDapagliflozin Propanediol | 60 | $63,977 |
| JanuviaSitagliptin Phosphate | 62 | $56,127 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $39,103 |
| Humalog Kwikpen U-100Insulin Lispro | 66 | $35,835 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $34,089 |
| Novolog FlexpenInsulin Aspart | 50 | $28,244 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 137 | $26,120 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $24,093 |
| SynthroidLevothyroxine Sodium | 344 | $22,852 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 46 | $12,446 |
| Liothyronine Sodium | 327 | $12,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,064 | $233,782168 claims |
| Novo NordiskOzempic, Novolog | $1,364 | $183,481151 claims |
| Boehringer IngelheimJardiance, Tradjenta | $233 | $91,89175 claims |
| AstraZenecaFarxiga | $1,053 | $63,97760 claims |
| MerckJanuvia | $142 | $56,12762 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $501 | $38,06034 claims |
| AbbVieSynthroid, Armour Thyroid | $522 | $24,479372 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $108 | $11,2481,125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Ashland
- Moussa AlhajAshland$121K
- Hazel YangAshland$7K
- Roberto Mitsui AkagiAshland$3K
- Harold BaysLouisville$12.9M
- Bradley EilermanFlorence$1.9M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Wael EidCovington$509K
- Lyle MyersLexington$434K
- Sathya KrishnasamyLouisville$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.